Nature Communications (Jan 2021)
A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy
- Shoichi Iriguchi,
- Yutaka Yasui,
- Yohei Kawai,
- Suguru Arima,
- Mihoko Kunitomo,
- Takayuki Sato,
- Tatsuki Ueda,
- Atsutaka Minagawa,
- Yuta Mishima,
- Nariaki Yanagawa,
- Yuji Baba,
- Yasuyuki Miyake,
- Kazuhide Nakayama,
- Maiko Takiguchi,
- Tokuyuki Shinohara,
- Tetsuya Nakatsura,
- Masaki Yasukawa,
- Yoshiaki Kassai,
- Akira Hayashi,
- Shin Kaneko
Affiliations
- Shoichi Iriguchi
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Yutaka Yasui
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Yohei Kawai
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Suguru Arima
- Takeda-CiRA Joint Program (T-CiRA)
- Mihoko Kunitomo
- Takeda-CiRA Joint Program (T-CiRA)
- Takayuki Sato
- Takeda-CiRA Joint Program (T-CiRA)
- Tatsuki Ueda
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Atsutaka Minagawa
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Yuta Mishima
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Nariaki Yanagawa
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Yuji Baba
- Takeda-CiRA Joint Program (T-CiRA)
- Yasuyuki Miyake
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- Kazuhide Nakayama
- Takeda-CiRA Joint Program (T-CiRA)
- Maiko Takiguchi
- Takeda-CiRA Joint Program (T-CiRA)
- Tokuyuki Shinohara
- Takeda-CiRA Joint Program (T-CiRA)
- Tetsuya Nakatsura
- Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
- Masaki Yasukawa
- Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine
- Yoshiaki Kassai
- Takeda-CiRA Joint Program (T-CiRA)
- Akira Hayashi
- Takeda-CiRA Joint Program (T-CiRA)
- Shin Kaneko
- Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University
- DOI
- https://doi.org/10.1038/s41467-020-20658-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
T-cell immunotherapies, such as CAR-T immunotherapy, are being developed against a wide variety of diseases. Here the authors report the feeder-free, scalable differentiation of human induced pluripotent cells (iPSCs) to T-cells with T-cell receptor dependent anti-tumour function in vitro and in vivo.
